Core Viewpoint - Berry Genomics announced that as of the date of the announcement, the company and its subsidiaries do not have any overdue debts, lawsuits, or guarantees related to judgments against them [2] Summary by Categories - **Debt Status** - The company confirmed that there are no overdue debts as of the announcement date [2] - **Legal Matters** - There are no ongoing lawsuits involving the company or its subsidiaries [2] - **Guarantees** - The company does not have any guarantees related to judgments where it has been ruled against [2]

Group 1 - Berry Genomics experienced a 5.25% increase in stock price, reaching 14.24 CNY per share, with a trading volume of 294 million CNY and a turnover rate of 6.48%, resulting in a total market capitalization of 5.034 billion CNY [1] - The company, established on April 14, 1997, specializes in high-throughput sequencing technology-based genetic testing, with revenue composition as follows: reagent sales 45.74%, medical testing services 31.24%, basic research services 18.33%, equipment sales 3.48%, and others 1.20% [1] Group 2 - The top circulating shareholder of Berry Genomics includes a fund from Yongying Fund, with the Medical Device ETF (159883) newly entering the top ten circulating shareholders in Q3, holding 1.5268 million shares, which is 0.46% of the circulating shares, resulting in an estimated floating profit of approximately 1.084 million CNY [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion CNY, showing a year-to-date return of 9.53% and a ranking of 3722 out of 4216 in its category, while experiencing a one-year loss of 1.36% and a ranking of 3671 out of 3937, with a cumulative loss of 46.89% since inception [2]

成都市贝瑞和康基因技术股份有限公司 关于为全资子公司的借款提供反担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 2025 年 8 月 20 日，成都市贝瑞和康基因技术股份有限公司（以下简称 "贝瑞基因""公司"）召开第十届董事会第十六次会议审议通过了《关于为 全资子公司提供担保的议案》，贝瑞基因全资子公司杭州贝瑞和康基因诊断技 术有限公司（以下简称"杭州贝瑞"）向杭州联合农村商业银行股份有限公司 高沙支行（以下简称"杭州联合农商行"）申请综合授信 4,000 万元，授信期 限 1 年。具体内容详见公司在巨潮资讯网上披露的《关于为全资子公司提供担 保的进展公告》（公告编号：2025-046）。公司于 2025 年 10 月 30 日召开第十 届董事会第十八次会议审议通过了《关于为全资子公司的借款提供反担保的议 案》，杭州市融资担保集团有限公司（以下简称"融资担保集团"）就上述授 信中 1,000 万元最高融资债权本金提供连带责任保证担保，公司在最高额人民 币 1,000 万元范围内，提供连带责任保证反担保。具体内容详见公司在巨潮 ...

Market Overview - The medical services sector experienced a decline of 0.34% on November 5, with Bai Cheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3969.25, up 0.23%, while the Shenzhen Component Index closed at 13223.56, up 0.37% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 45.33, up 4.93% [1] - Berry Genomics (000710) at 14.13, up 4.20% [1] - New Mileage (002219) at 2.33, up 2.19% [1] - Significant decliners included: - Zicheng Pharmaceutical (301096) at 66.55, down 9.03% [2] - Digital Human (920670) at 17.93, down 6.42% [2] - Chengda Pharmaceutical (301201) at 31.10, down 6.13% [2] Capital Flow - The medical services sector saw a net outflow of 847 million yuan from institutional investors, while retail investors contributed a net inflow of 812 million yuan [2][3] - The table of capital flow indicates that: - Berry Genomics had a net outflow of 53.09 million yuan from institutional investors [3] - New Mileage experienced a net inflow of 10.47 million yuan from institutional investors [3] - Medical domain stocks like Meidi (688202) and Boji Pharmaceutical (300404) also showed varied capital flows [3]

Core Insights - The Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical Products Administration (NMPA) in China, enabling the use of PacBio HiFi sequencing for complex genetic conditions, starting with thalassemia [1][2] - This approval represents the world's first regulatory clearance for a clinical-grade long-read sequencer, marking a significant advancement in precision medicine and genomic testing in China [2] - The Sequel II CNDx system allows clinicians to obtain a comprehensive view of the genome in a single test, accurately capturing various genetic variants [3] Company Developments - The approval of the Sequel II CNDx system, in conjunction with Berry Genomics' clinical thalassemia assay, establishes the first end-to-end long-read sequencing workflow for hospitals and diagnostic labs in China [4] - PacBio's technology utilizes Single Molecule, Real-Time (SMRT) technology, which is capable of delivering high accuracy and long read lengths of 20 kb and greater, enhancing the analysis of DNA molecules [5] - Berry Genomics plans to expand its capabilities to include additional clinical assays for various genetic disorders, demonstrating a commitment to improving diagnostic accuracy [6] Industry Impact - The NMPA approval signifies a major advancement for China's clinical genomics ecosystem, allowing for in-country testing with reduced turnaround times and improved diagnostic yield compared to existing technologies [6] - As demand for comprehensive genomic testing increases, PacBio aims to enhance the clinical utility of HiFi sequencing through partnerships and investments in AI-powered analysis [6] - The collaboration between PacBio and Berry Genomics reflects a shared vision to provide clinicians with accurate and comprehensive genomic insights, potentially transforming patient care [6]

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Market Overview - The medical services sector experienced a decline of 0.59% on November 3, with "Digital Human" leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Top Performers in Medical Services - Baicheng Pharmaceutical (301096) saw a significant increase of 19.15%, closing at 68.99 with a trading volume of 312,000 shares and a transaction value of 2.061 billion [1] - Berry Genomics (000710) rose by 6.11%, closing at 13.89 with a trading volume of 493,700 shares and a transaction value of 690 million [1] - YaoKang Bio (688046) increased by 4.77%, closing at 18.67 with a trading volume of 82,900 shares and a transaction value of 154 million [1] Underperformers in Medical Services - Digital Human (920670) led the decline with a drop of 6.20%, closing at 17.70 with a trading volume of 153,800 shares and a transaction value of 272 million [2] - Yixin Information (688710) fell by 5.70%, closing at 44.68 with a trading volume of 27,400 shares and a transaction value of 123 million [2] - Haoyuan Pharmaceutical (688131) decreased by 5.50%, closing at 75.40 with a trading volume of 79,400 shares and a transaction value of 601 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 712 million from institutional investors, while retail investors saw a net inflow of 466 million [2][3] - Berry Genomics (000710) had a net inflow of 152 million from institutional investors, but a net outflow of 68.58 million from retail investors [3] - Baicheng Pharmaceutical (301096) recorded a net inflow of 124 million from institutional investors, with a net outflow of 99.78 million from retail investors [3]

Company Highlights - Tianqi Co., Ltd. signed a strategic cooperation framework agreement with Foxconn Automotive, planning to deploy no less than 2,000 embodied intelligent robots in the next five years [1] - Tianhua New Energy's actual controllers plan to transfer 12.95% of shares to CATL at a price of 24.49 yuan per share, which is a 19% discount compared to the closing price [2] - Zhenyu Technology plans to invest 21.1 billion yuan in humanoid robot precision module and component projects [3] - Taiyuan Heavy Industry disclosed false financial data in its annual report, leading to a change in its stock name to "ST Tai Heavy" starting November 4 [4] Investment & Contracts - East Asia Machinery plans to invest 400 million yuan to build an intelligent manufacturing base for air compressors and core components in Central China [12] Shareholding Changes - TuoStar's director plans to reduce his holdings by up to 0.95% [14] - Shanghai Fosun Pharmaceutical plans to reduce its holdings in Shanhe Pharmaceutical by up to 3% [16] Business Performance - Pingzhi Information reported a total procurement amount of 469 million yuan for server-related products since May [17] - Berry Genomics received medical device registration for the world's first clinically approved third-generation sequencing platform, Sequel® IICNDx [18] Contracts & Project Awards - Hopu Co., Ltd. signed a 5.2 billion yuan procurement contract for a storage system [20] - Qiaoyin Co., Ltd. received a bid notification for a 5.12 billion yuan urban sanitation integration project [20] Stock Price Movements - Hezhong China experienced a 46.56% increase in stock price over four consecutive trading days, indicating potential irrational speculation [22] Other Announcements - Huaxin Cement will change its stock name to Huaxin Building Materials starting November 6 [23]

Core Insights - Berry Genomics (000710.SZ) announced that its subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its third-generation sequencing instrument, Sequel II CNDx, marking it as the first clinically approved third-generation sequencing platform globally [1][2] Group 1: Product Approval and Features - The Sequel II CNDx is the first third-generation sequencing platform approved for clinical use, enabling rapid implementation of third-generation sequencing solutions in local laboratories [1] - The approval allows for "one machine, multiple uses" and "mixed loading," which reduces sample waiting times, accelerates report cycles, and enhances service quality within hospitals [1] Group 2: Clinical Applications and Impact - The clinical approval of Sequel II CNDx will enhance the birth defect prevention system and significantly improve the detection capabilities for complex single-gene diseases [2] - Berry Genomics aims to deepen the clinical application of third-generation sequencing technology by optimizing AI algorithms and local deployment plans, making testing services more precise, efficient, and economical for families [2] - The large-scale application of third-generation sequencing technology is expected to accelerate major public health initiatives, such as the prevention of birth defects, both in China and globally [2]

Group 1 - Berry Genomics' subsidiary, Hangzhou Berry Genomics and Health Technology Co., Ltd., has received the NMPA medical device registration certificate for its third-generation sequencing instrument, Sequel® II CNDx, making it the first clinically approved third-generation sequencing platform globally [1] - The approval of Sequel® II CNDx enables rapid implementation of third-generation sequencing solutions in local clinical laboratories, reducing sample waiting times, accelerating report cycles, and enhancing service quality within hospitals [1] - Berry Genomics has achieved full self-production of third-generation sequencing testing reagents and the local deployment of an intelligent report interpretation system, providing comprehensive localized services from sample collection to report management [1] Group 2 - The clinical approval of Sequel® II CNDx enhances the birth defect prevention system and significantly improves the detection capabilities for complex single-gene diseases [2] - Berry Genomics aims to deepen the clinical application of third-generation sequencing technology by optimizing AI algorithms and local deployment plans, making testing services more precise, efficient, and economical for families [2] - The large-scale application of third-generation sequencing technology is expected to accelerate the advancement of major public health projects, such as birth defect prevention, both in China and globally [2]